NMTR - NMTR STOCK NEWS

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced that CEO John Temperato will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The event will be held virtually, with on-demand presentations starting September 13 at 7:00 am ET for 90 days. Investors can schedule one-on-one meetings with executives. The company is focused on innovative treatments for rare digestive diseases, advancing key products like vurolenatide and larazotide. For more details, visit www.9meters.com.

9 Meters Biopharma (Nasdaq:NMTR) announced participation in Citi's 16th Annual BioPharma Virtual Conference from September 8-10, 2021. CEO John Temperato will represent the company, inviting investors to schedule virtual one-on-one meetings. 9 Meters focuses on developing treatments for rare gastrointestinal disorders, advancing therapies like vurolenatide for short bowel syndrome and larazotide for celiac disease. For information, visit www.9meters.com.

9 Meters Biopharma has received a Study May Proceed letter from the FDA to initiate a Phase 2a clinical trial for larazotide in treating multisystem inflammatory syndrome in children (MIS-C). The trial will be conducted by EBRIS at Massachusetts General Hospital for Children, targeting children affected by this serious COVID-19 complication. The study aims to evaluate larazotide's efficacy in managing the inflammatory response associated with MIS-C. If successful, it may lead to regulatory discussions about larazotide's future development in this context.

9 Meters Biopharma (Nasdaq:NMTR) recently reported its Q2 2021 financial results, highlighting the initiation of the Phase 2 VIBRANT study for vurolenatide targeting short bowel syndrome (SBS) and the acquisition of a humanized anti-GIP monoclonal antibody from Lobesity. The company expects to release Phase 2 data in Q4 2021. As of June 30, 2021, 9 Meters had $64 million in cash, sufficient to fund operations into 2023. The net loss for Q2 totaled $8.3 million, an improvement from a loss of $44.6 million in Q2 2020.

9 Meters Biopharma (NASDAQ:NMTR) announced participation in the Biopharma Spotlight Series: Innovation in GI Conference Call on August 12, 2021. The call will feature insights on Short Bowel Syndrome, led by management including John Temperato, President & CEO, and Patrick Griffin, Chief Medical Officer. It is scheduled for 11:35 AM ET. Interested parties can access the webcast and a replay will be available for 90 days. The company focuses on innovative treatments for rare digestive diseases.

9 Meters Biopharma (NASDAQ: NMTR) has acquired global development rights to the humanized monoclonal antibody NM-136 from Lobesity LLC. This acquisition focuses on the novel target, glucose-dependent insulinotropic polypeptide (GIP), with the first indication planned for Prader-Willi Syndrome. Ongoing IND-enabling studies are expected to lead to first-in-human trials in 2023. The deal includes a $5 million upfront payment and potential milestone payments totaling up to $95.5 million. This strategic move broadens 9 Meters’ pipeline while maintaining its financial stability through 2023.

9 Meters Biopharma (NASDAQ:NMTR) will participate in the William Blair Biotech Focus Conference on July 15, 2021, from 2:00 to 2:45 p.m. ET. CEO John Temperato will engage in a virtual fireside chat, inviting investors to join via webcast. The company specializes in rare gastroenterology needs, focusing on drug development for conditions like short bowel syndrome and celiac disease. A replay of the presentation will be available for 30 days post-event. For more information, visit 9meters.com.

9 Meters Biopharma (NASDAQ:NMTR) has officially joined the Russell 3000 and Russell 2000 Indexes as of June 28, 2021. This inclusion highlights the company’s recent achievements in the field of gastroenterology, particularly as it advances its therapies for rare conditions. The Russell Indexes are pivotal for investment managers, benchmarking around $9 trillion in assets. CEO John Temperato notes that this move will enhance the company’s visibility among investors at a critical time as they progress towards significant milestones.

9 Meters Biopharma has initiated the largest Phase 2 placebo-controlled trial for vurolenatide, targeting adults with short bowel syndrome (SBS). The VIBRANT study aims to enroll approximately 22 patients across 7 U.S. sites, assessing the drug's safety and efficacy with topline results expected in Q4 2021. Vurolenatide, a long-acting GLP-1 agonist, has shown potential in improving bowel function in previous trials. The study's primary endpoint is total stool output, paving the way for a potential Phase 3 study in the same timeframe.